In anticipation of the imminent commercialisation of the Kaleido insulin delivery system, the ViCentra Board are announcing today a change in management that prepares the Company for the next phase in its future. Joseph Cefai stepped down as CEO on April 1st 2016....

January 16th, 2016. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercializing the Kaleido insulin pump system for people with diabetes. The...